Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with macrolide (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Overall quality of life measured at the end of · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Serum ferritin (ng/mL) · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Bacterial infection · non‐anaemic, iron‐deficient adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Peak oxygen consumption taken at the end of · non‐anaemic, iron‐deficient adults
1 finding from 1 review
Serious adverse events · non‐anaemic, iron‐deficient adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events mild adverse events · non‐anaemic, iron‐deficient adults
It is very uncertain whether intravenous iron changes mild adverse effects compared with placebo (very low certainty).
1 finding from 1 review